Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.96 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.96 |
| ▸ | CSNK2B | P67870 | 8/20 | 0.96 |
| ▸ | SGK1 | O00141 | 1/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 1/20 | 0.96 |
| ▸ | GMNN | O75496 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.96 |
| ▸ | CDK2 | P24941 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | THPO | P40225 | 1/20 | 0.96 |
| ▸ | MTOR | P42345 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263870 | 0.98 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL10323132 | 0.71 | PIM1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1817323 | 0.70 | CSNK2A1 (0.54) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1759407 | 0.69 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1816869 | 0.68 | CSNK2A1 (0.53) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL3866440 | 0.66 | CSNK2A1 (0.60) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL3867762 | 0.66 | CSNK2A1 (0.60) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1760582 | 0.66 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1759675 | 0.65 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1 | |
| SCHEMBL3868111 | 0.65 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | SELVITA SP. Z.O.O. (PL) | 2009-09-24 | — | — | US | disclosed |
| US-7528259-B2 | Derivatives of 4,5,6,7-tetrabromobenzimidazole and method of their preparation | SELVITA SP. Z O. O. (PL) | 2009-05-05 | — | — | US | disclosed |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | SELVITA S.A. (PL) | 2007-09-13 | — | — | US | disclosed |
| EP-1778647-A1 | NEW DERIVATIVES OF 4, 5, 6, 7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | FUNDACJA ROZWOJU DIAGNOSTYKI I TERATII (PL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005092866-A1 | NEW DERIVATIVES OF 4, 5, 6, 7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | FUNDACJA ROZWOJU DIAGNOSTYKI I TERATII (PL) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | CYP3A4, IL4I1, CYP4B1 | CSNK2A1 1059/4885CSNK2A2 1023/4885CSNK2B 840/4885 |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | CSNK2A2, CSNK2A1, CSNK2B | CSNK2A1 2/4885CSNK2A2 1/4885CSNK2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.